A Comprehensive Review of Punicagranatum (Pomegranate) Properties in Toxicological, Pharmacological, Cellular and Molecular Biology Researches

authors:

avatar Hamid Reza Rahimi a , avatar Mohammad Arastoo b , avatar Seyed Nasser Ostad a , *

Department of Toxicology and Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Research Center for Science and Technology in Medicine, Tehran University of Medical Sciences,
Iranian Journal of Pharmaceutical Research : IJPR: Vol.11, issue 2; 385-400
article type: Original Article
received: August , 2011
accepted: October , 2011
DOI: https://doi.org/10.22037/ijpr.2012.1148

how to cite: Rahimi H R, Arastoo M, Ostad S N. A Comprehensive Review of Punicagranatum (Pomegranate) Properties in Toxicological, Pharmacological, Cellular and Molecular Biology Researches. Iran J Pharm Res. 2012;11(2):e125841. https://doi.org/10.22037/ijpr.2012.1148.

Abstract

Punica granatum (Pg), commonly known as pomegranate (Pg), is a member of the monogeneric family, Punicaceae, and is mainly found in Iran which is considered to be its primary centre of origin. Pg and its chemical components possess various pharmacological and toxicological properties including antioxidant, anti-inflammatory (by inhibiting pro-inflammatory cytokines), anti-cancer and anti-angiogenesis activities. They also show inhibitory effects on invasion/motility, cell cycle, apoptosis, and vital enzymes such as cyclooxygenase (COX), lipooxygenase (LOX), cytochrome P450 (CYP450), phospholipase A2 (PLA2), ornithine decarboxylase (ODC), carbonic anhydrase (CA), 17beta-hydroxysteroid dehydrogenase (17β-HSDs) and serine protease (SP). Furthermore, they can stimulate cell differentiation and possess anti-mutagenic effects. Pg can also interfere with several signaling pathways including PI3K/AKT, mTOR, PI3K, Bcl-X, Bax, Bad, MAPK, ERK1/2, P38, JNK, and caspase. However, the exact mechanisms for its pharmacological and toxicological properties remain to be unclear and need further evaluation. These properties strongly suggest a wide range use of Pg for clinical applications. This review will discuss the areas for which Pg has shown therapeutic properties in different mechanisms.

Introduction

Punica granatum (Pomegranate) is a small tree which measures between five and eight meters tall and mainly found in Iran, the Himalayas in northern India, China, USA and throughout the Mediterranean region (1). Pg is one of the important endemic plants of Iran, growing in most regions throughout the country, in arid and semiarid regions due to its ability to adapt to adverse ecological conditions. Over 764 cultivars of Punica granatum (Pg) have been collected during a germplasm collection and grown in the cities of Saveh and Yazd (Iran), all of which possess specific fruit characteristics including size, color, taste, time of ripening, and disease resistance (2). The Pg can be also divided into several anatomical compartments including seed, juice, peel, leaf, flower, bark, and root with each possessing interesting pharmacological and toxicological activities. The edible fruit is a berry which is about 5-12 cm in diameter with a rounded hexagonal shape, thick reddish skin and around 600 seeds, each surrounded by a water-laden pulp (aril) ranging in color from white to deep red or purple, the aril is the edible part of the fruit. The seeds are embedded in a white, spongy, astringent pulp (3). According to the holy Quran, pomegranates grow in the gardens of paradise and the Quran has recited the Pg twice as an example of god’s good creations.

The fruit of the Pg has extensively been used as a traditional remedy against acidosis, dysentery, microbial infections, diarrhea, helminth infection, hemorrhage and respiratory pathologies (4). Pg seeds have also been shown to contain the estrogenic compounds, estrone and estradiol (4). Furthermore, the dried pericarp and the juice of the fruit are considered beneficial for treatment of colic, colitis, menorrhagia, oxyuriasis, headache, diuretic, acne, piles, allergic dermatitis, and treatment of oral diseases (5). Recent studies have shown new scientific investigations for the traditional uses of Pg (5).

Chemical contents

Pg contains chemical components in its different compartments, which may possess various pharmacological and toxicological activities (6). These components are summarized in Table 1 (6).

Antioxidant properties

Oxidative stress (OS) produces toxic metabolites (7) which can initiate and promote cancers (8, 9). Consumption of polyphenoles and flavonoids are beneficial for the prevention of cardiovascular, inflammatory, and other diseases by preventing OS that induces lipid peroxidation in arterial macrophages and in lipoproteins (10, 11). The presence of antioxidants has been reported in Pg juice (10). Pg contains some species of flavonoids and anthocyanidins (delphinidin, cyaniding and pelargonidin) in its seed oil and juice (6) and shows antioxidant activity three times greater than green tea extract (12). Pg fruit extracts exhibit scavenging activity against hydroxyl radicals (13) and superoxide anions, which could be related to anthocyanidins (6). The antioxidant action of Pg is observed, not only through its scavenging reactions, but also by its ability to form metal chelates (14). Studies have indicated that methanolic extracts from the peel of Pg has a broad spectrum of antioxidant activities which were evaluated by 1,1-diphenyl 2-picrylhydrazyl (DPPH) free radical scavenging, phosphomolybdenum, Ferric (Fe3+) Reducing Antioxidant Power (FRAP), and Cupric (Cu2+) Reducing Anti-oxidanrt Capacity (CUPRAC) assays (14, 15). Studies have looked at the beneficial effects of pomegranates antioxidant activity in-vivo and in-vitro and have shown that Pg juice consumption causes a decrease in procarcinogen activation through CYP activity/expression (CYP1A2 and CYP3A) (16), protection of rat gastric mucosa from ethanol or aspirin toxicity (17), protection of neonatal rat brain from hypoxia (18), reduction of hepatic OS (19), reversal of proatherogenic effects which are induced by perturbed shear stress (20), protective effects against UVA- and UVB-induced cell damage and the potential use of Pg polyphenolics in topical applications (21). Other studies have also shown the protective effects of Pg on the cardiovascular system, including reduction of LDL and cholesterol (22, 23), anti-hypertension action by combating OS induced by diabetes and angiotensin II (24), reduction of carotid arterial stenosis and increase of endothelial nitric oxide (NO) syntheses (25, 26); and suggest the Pg as part of a heart-healthy diet through inhibiting of OS mechanism (27).

Anti-inflammatory effect

Acute inflammation is a beneficial host response for prevention of tissue injury, but it may also cause immune-associated diseases such as rheumatoid arthritis, inflammatory bowel disease and cancers (28, 29). Interestingly, Pg, Pg has been shown to inhibit inflammation by different mechanisms.

Cyclooxygenase (COX) and lipooxygenase (LOX), which are key enzymes in the conversion of arachidonic acid to prostaglandins and leukotrienes (important inflammatory mediators), respectively, are inhibited by Pg (30, 31). Non-steroidal anti-inflammatory drugs (NSAIDs) have more adverse effects on cardiovascular function by inhibiting COX and suppressing PGI2 (prostacyclin) in comparison to Pg (32). Ahmed et al. have shown that Pg has a significant inhibitory effect on osteoarthritis (OA) by suppressing the expression of matrix metalloproteinases (MMPs) in OA chondrocyte cultures and preventing collagen degradation. It may also inhibit joint destruction in OA patients (33). Pro-inflammatory cytokines such as IL-1β play an important role in OA pathogenesis (34). IL-1β induces the expression of MMPs, especially MMP-1 and MMP-13, which are associated to the irreversible breakdown of cartilage matrix through digestion of type-II collagen and the consequent release of matrix proteoglycan from the cartilage (34). Furthermore, Pg has shown anti-inflammatory effects in a colitis rat model (35). However, studies have shown the inhibitory effect of Pg on production of pro-inflammatory cytokines (34-36). These studies demonstrate that Pg inhibits the p38-mitogen-activated protein kinase (p38-MAPK) pathway and transcription factor, NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells). Activation of p38-MAPK and NF-kB are associated with increased gene expression of TNF-α, IL-1β, MCP1, iNOS, and COX-2 agents which are critical mediators of inflammation (36). Studies have also shown that administration of 50 mg/kg of Pg extract for 28 days causes a decrease in malondialdehyde (MDA), TNF-α, and IL-1β levels in rats with liver fibroses (37). Also, Shukla et al. showed that pretreatment with 13.6 mg/kg of Pg extract decreased the arthritis incidence and lowered IL-6 and IL-1β levels in animal model of rheumatoid arthritis (38).

Carcinogenesis

Pg possesses inhibitory effects on different type of cancers such as prostate (39,40), breast (41), colon (42,43), and lung cancers (44). Different mechanisms have been outlined for pomegranates anti-cancer activities in these studies. Pg inhibits NF-kBand cell viability of prostate cancer cell lines in a dose-dependent manner in the LAPC4 xenograft model, in-vitro (45). Pg polyphenols, ellagitannin-rich extract and whole juice extract inhibited gene expression of HSD3B2 (3beta-hydroxysteroid dehydrogenase type 2), AKR1C3 (aldo-ketoreductase family 1 member C3) and SRD5A1 (steroid 5alpha reductase type 1), which are key androgen-synthesizing enzymes in LNCaP, LNCaP-AR, and DU-145 human prostate cancer cells (46). Because Pg inhibits CYP activity/expression which is necessary for activation of procarcinogens, it may have anti-carcinogenesis effects (16). Some metabolites of pomegranates chemical components such as 3,8-dihydroxy-6H-dibenzo[b, d]pyran-6-one (urolithin A, UA) which is produced from Ellagitannins (ETs) may also possess anti-cancer effects (46). Treatment with (50-150 μg/mL) pomegranate fruit extract (PFE) for 72 h was found to result in a significant inhibition of lung cancer, with dose-dependent arrest of cells in G0/G1 phase of the cell cycle, induction of WAF1/p21 and KIP1/p27, decrease in the protein expressions of cyclins D1, D2, and E, decrease in cyclin-dependent kinase (cdk) 2, cdk4 and cdk6 expression, phosphorylation of MAPK proteins, inhibition of PI3K, phosphorylation of Akt at Thr308, NF-kB and IKK (inhibitor of kappa kinase) alpha, degradation and phosphorylation of IκB, Ki-67 and PCNA (44). Also, the levels of Bax and Bcl-2 were altered by PE in PC-3 cell line (47).

Angiogenesis

Angiogenesis is an important process for the development of new blood vessels, which is essential in supplying oxygen and nutrition for tumor growth and progression of cancers (48). Therefore, angiogenesis is a possible target for cancer prevention strategy (49, 50). Fibrocytes are important in angiogenesis, as they lay the requisite intracellular infrastructure of blood vessels (51), secrete extracellular matrix degrading enzymes such as MMP-9 which stimulate endothelial cell invasion, and secrete pro-angiogenic factors such as vascular endothelial growth factor (VEGF), basic fibrocyte growth factor (bFGF), and interleukins (IL) (52). Interestingly, recent study has shown the ability of Pg to inhibit angiogenesis (53). Toiet et al. evaluated the anti-angiogenic potential of Pg by measuring vascular endothelial growth factor (VEGF), IL-4, and migration inhibitory factor (MIF) in the conditioned media of estrogen sensitive (MCF-7) or estrogen resistant (MDA-MB-231) human breast cancer cells, and immortalized normal human breast epithelial cells (MCF-10A). VEGF was strongly decreased in MCF-10A and MCF-7, however, MIF was increased in MDA-MB-231, showing significant potential for inhibitory effects of angiogenesis by Pg fractions on human umbilical vein endothelial cells (HUVEC) (53).

Invasion and motility

Understanding the mechanisms of tumor cell invasion and metastasis could prove to be important for preventing tumor cell spread. MMP-1, MMP-2, and MMP-9, are a family of zinc-dependant endoproteinases which are most closely linked with metastasis of cancer cells (54-57). Activity of MMPs are regulated on certain levels including transcriptional control, proenzyme activation, and inhibition of activated MMPs by non specific inhibitors such as α2-macroglobulin (58), and specific endogenous inhibitors such as tissue inhibitors of metalloproteinase (TIMP) (58). TIMPs bind to the active site of MMPs and block access of MMPs to their substrates (58). Caffeic acid phenethyl ester (CAPE), a compound of Pg which is also derived from honey bee propolis has shown dose-dependent decreases in MMP and TIMP-2 mRNA levels in HT1080 human fibrosarcoma cells, as detected by reverse transcriptase-polymerase chain reaction (RT-PCR). Gelatin zymography analysis confirmed this when compared to controls (57). This study shows the role of CAPE as a potent anti-metastatic agent, which can significantly inhibit the metastatic and invasive capacity of malignant cells (57). Pg has shown dose-dependent inhibition effect on NF-kB-dependent reporter gene expression which is associated to proliferation, invasion, and motility in aggressive breast cancer phenotypes. This effect is behind to decrease RhoC and RhoA protein expression, suggests a role for these extracts in lowering the metastatic potential of aggressive breast cancer species (60). Four pure chemicals, ellagic acid, caffeic acid, luteolin, and punicic acid, obtain from the Pg fruit were presented as potential inhibitors of in-vitro invasion of human PC-3 prostate cancer cells in an assay employing Matrigel artificial membranes (61).

Cell cycle arrest

The cell cycle is a series of events which takes place in a cell, leading to its division and duplication. It consists of four distinct phases; G1 phase, S phase (synthesis), G2 phase (collectively known as interphase) and M phase (mitosis). Multiple checkpoints have been identified to verify whether the processes at each phase of the cell cycle have been accurately completed before progression into the next phase. Cell cycle may be altered following exposure to Pg. Previous studies have suggested several mechanisms for these effects, such as modulation of cell signaling molecules in the cell cycle machinery. Punica granatum extract (PE) inhibited the proliferation of mouse mammary cancer cell line (WA4), derived from mouse MMTV-Wnt-1 mammary tumors in a time and concentration-dependent manner through an arrest of cell cycle progression in the G0/G1 phase (62). Ellagitannins, derived from Pg juice, and their metabolites, urolithins exhibit dose and time-dependent decreases in cell proliferation and clonogenic efficiency of HT-29 cells through cell cycle arrest in the G0/G1 and G2/M stages of the cell cycle followed by induction of apoptosis (43). Moreover, Pg treatment induced a dose-dependent arrest in the G0/G1 phase of the cell cycle which was assessed by DNA cell cycle analysis in the lung cancer cell line (A549) (63). Pg pretreatment of normal human epidermal keratinocytes (NHEK) has been found to increase the cell cycle arrest induced by UVA in the G1 phase of the cell cycle (64). Furthermore, Androgen-independent cell line, DU 145 has shown a significant increase from 11% to 22% in G2/M cells (p < 0.05) by treatment with (35 μg/mL) Pg cold-pressed oil (65). Ellagic acid is a phenolic compound, which may belong to Pg, and induces cell cycle arrest and apoptosis in T24 human bladder cancer cells in-vitro through induced G0/G1 phase arrest, increased p53 and p21 and decreased cyclin-dependent kinase (Cdk2) gene expression (65). Cdks as the mainly one Cdk4 is a key key molecule in the regulation of cell cycle progression at the G1-S phase restriction point is inhibited by p16 (INK4a), a tumor suppressor. It has been reported that the N-terminal of different truncated p16 (INK4a) molecules is not crucial for the interaction with Cdk4 (66). However, Ostad et al. have previously shown that the C-terminal domain of p16 (INK4a) is adequate in inducing cell cycle arrest, growth inhibition, and CDK4/6 interaction (68).

Apoptosis

Apoptosis is the process of programmed cell death, which is a useful marker for predicting tumor response after anti-cancer treatment. Pg causes apoptosis by different mechanisms. PE has been found to induce apoptosis by increasing caspase-3 activity in a mouse mammary cancer cell line (WA4) (62). In addition, Pg extracts and punic acid, an omega-5 long chain poly unsaturated fatty acid derived from Pg, have been shown to induce apoptosis in both an estrogen in sensitive breast cancer cell line (MDA-MB-231) and an estrogen sensitive cell line developed from MDA-MB-231 cells (MDA-ERalpha7) through lipid peroxidation and the PKC (Protein kinase C) signaling pathway (69). They also cause disruption to the cellular mitochondrial membrane (69). The relationship between pg-induced apoptosis in human prostate cancer cells (LAPC4) and the IGF/IGFBP system have been investigated (70). POMx (a highly potent Pg extract prepared from skin and arils, minus the seeds) and IGFBP-3 have been shown to synergistically stimulate apoptosis. Inhibition of cell growth resulted in increased JNK phosphorylation and decreased Akt and mTOR activation (70). Pg treatment of normal human epidermal keratinocytes (NHEK) inhibited UVB-mediated activation of MAPK and NF-kB pathways, as well as other signal transducers and activators of the apoptosis pathway including transcription 3 (STAT3), PKB/AKT, ERK1/2, mTOR, PI3K, Bcl-X(L) (antiapoptotic protein), Bax and Bad (proapoptotic proteins) (64). The role of MAPK signaling pathways and effects of PI3K/AKT, ERK1/2, P38, and JNK on epidermal growth factor (EGF) signaling in proliferation of human mesenchymal stem cells (hMSCs) have been shown in-vitro (71). The cell growth is controlled by the interaction of survival and cell growth arrest pathways and the activity of survival pathways such as Akt and ERK1/2 with regard to XIAP (inhibitor of apoptosis) in serum starvation has been investigated and the survival role for ERK in serum starvation has been reported (72). Recently, the Pg inhibition of cell growth, followed by apoptosis of highly aggressive human prostate carcinoma PC3 cells through modulations in the cyclin kinase inhibitor-cyclin-dependent kinase machinery have been shown by Malik et al. These events were associated to alterations in the levels of Bax and Bcl-2, shifting the Bax: Bcl-2 ratio in favor of apoptosis (47). Ellagitannins (ETs) and hydrolysable tannins, which are found in Pg and their hydrolyzed product, as well as ellagic acid (EA), have been reported to induce apoptosis in human colon cancer Caco-2 cells through down-regulation of cyclins A and B1, upregulation of cyclin E, cell-cycle arrest in the S phase, induction of apoptosis via intrinsic pathways (FAS-independent, caspase-8 independent) through bcl-XL down-regulation with mitochondrial release of cytochrome c into the cytosol as well as activation of initiator caspase-9 and effector caspase-3 (73). Induction of Bax and Bak (proapoptotic), down-regulation of Bcl-X(L) and Bcl-2 (anti-apoptotic), induction of WAF1/p21 and KIP1/p27, a decrease in cyclins D1, D2, and E, and a decrease in cdk2, cdk4, and cdk6 expression have been shown to occur in prostate cancer PC3 cells, following Pg treatment (74).

Punica granatum effects on vital enzymes

Enzymes are proteins that catalyze biochemical/chemical reactions. Pg has been shown to inhibit different enzymes including phospholipase A2 (PLA2) (that catalytically hydrolyzes the bond releasing arachidonic acid and lysophospholipids) (75), cyclooxygenase (COX), lipooxygenase (LOX) (30), cytochrome P450 (76) and ornithine decarboxylase (ODC) (77) which plays a role in the urea cycle and catalyzes the decarboxylation of ornithine to polyamines such as putrescine. Polyamines regulate growth processes and stimulate the growth of cancer (78). Carbonic anhydrase (CA) that catalyzes the hydration of carbon dioxide to form bicarbonate (HCO3-) is also inhibited (79). CA inhibitors such as Pg have been shown to inhibit cancer cell growth in-vitro and in-vivo (80). Aromatase is enzyme responsible for a key step in the biosynthesis of estrogens and catalyzes the formation of estrone and estradiol, which is inhibited by Pg (81). One of the possible mechanisms in which Pg can inhibit breast cancer is its inhibitory effect on aromatase and 17 beta-hydroxysteroid dehydrogenase enzymes (17β-HSDs), as well as its anti-estrogenic activity (41). Furthermore, ellagitannins (ET) and urolithin B (UB), which are found in relatively high quantities in Pg, have been shown to most effectively inhibit aromatase activity in a live cell assay (82). Serine protease (SP) is another enzyme which is inhibited by Pg. SP is enzymes in which one of the amino acids in the active site is serine. Protease plays an essential role in modulating the turnover of extracellular matrix (EC), which provides morphological support for cell growth and differentiation (83). Furthermore, protease has a verity of important functions including angiogenesis, vasculogenesis, apoptosis, and cell migration/invasion (84). Ellagic acid and punicalagin, from Pg, have shown lower inhibitory effects on alpha-secretase (TACE) and other serine proteases such as chymotrypsin, trypsin, and elastase, thus indicating that they are relatively specific inhibitors of beta-secretase (BACE1) (85). Other studies have shown that catechin and epicatechin (epigallocatechin-3-gallate) (86-88), which are present in Pg (89), can inhibit SP.

Cellular differentiation

Cellular differentiation, in developmental biology, is the process by which a less specialized cell becomes a more specialized cell type. Study has shown that Pg stimulates the differentiation of osteoblastic MC3T3-E1 cells and affects the function of these cells (4). Pg seed oil (but not aqueous extracts of fermented juice, peel or seed cake) has been shown to stimulate keratinocyte proliferation in monolayer culture, without effecting fibroblast function, and as a result facilitates skin repair and promotes regeneration of dermis and epidermis (56). flavonoid-rich fractions from fermented Pg juice and aqueous extraction of Pg pericarps are strong promoters of differentiation in human HL-60 promyelocytic leukemia cells, which are detected by nitro blue tetrazolium reducing activity, non specific esterase activity, specific esterase activity, and phagocytic activity, whereas flavonoid-rich fractions from fresh Pg juice only show a relatively mild differentiation-promoting effect. Furthermore, the effect of Pg on differentiation has been observed in breast and prostate cell lines (90).

Anti-mutagenicity

A mutagen is a physical orchemical agent that alters the genetic material of an organism, usually DNA, permanently and thus increases the frequency of mutations above the natural background level Mutagenicity is the capacity of a chemical or physical agent to cause such permanent change. It has been shown that Pg peel fractions, especially methanol, has anti-mutagenic activities as was detected by the Ames Salmonella/microsome assay against sodium azide (NaN3), methyl methane sulphonate (MMS), 2-aminofluorene (2-AF), and benzo(a)pyrene (B(a)P) induced mutagenicity in Salmonella typhimurium (TA97a, TA98, TA100 and TA102) tester strains (15). Methanolic extract of Pg (15 mg/plate) shows the highest anti-mutagenic activity in TA 100 cells (91).

Clinical application

Considering the mentioned properties, Pg has the potential to be used in many clinical applications. Studies have shown that Pg inhibits prostate cancer cell growth, induces apoptosis in PC-3 cells (highly aggressive prostate carcinoma cells), suppresses invasion of PC-3 cells and decreases proliferation of DU-145 prostate cancer cells in-vitro (52). Treatment of HT-29 colon cancer cells has been indicated by Pg juice through decreasing COX-2 expression and inhibiting inflammatory cell signaling processes which may cause cancer initiation and progression (92). Furthermore, COX-2 is involved in the proliferative response of human periodontal fibroblast (HPLF) cells to Emdogain (EMD) (93). There has been a correlation between inducible nitric oxide (iNOS) synthase and COX-2 expression in human colorectal adenocarcinoma. In fact, a possible link between advanced stages of this disease and higher expression of iNOS and COX-2 has been shown by Habibollahi et al. (94).

Table 1

Phytochemicals present in Punina granatum (pomegranate)

Pomegranate PhytochemicalsFormulaMolecular weight (MW)Plant Part
Ellagitannins and Gallotannins
2,3-(S)-HHDP-D-glucoseaC20H18O14482.35Bark, peel
CastalaginC41H26O26934.63Bark
CasuariinC34H24O22784.54Bark
Casuarinin936.65Bark, pericarp
CorilaginC27H22O18634.45Fruit, leaves, pericarp
Cyclic 2,4:3,6-bis(4,4′,5,5′,6,6′-hexahydroxy [1,1′-biphenyl]- 2,2′-dicarboxylate) 1-(3,4,5-trihydroxybenzoate) b-D-GlucoseC41H28O26936.65leaves
Granatin AC34H24O23800.54Pericarp
Granatin BC34H28O27952.64Peel
PedunculaginC34H24O22784.52Bark, pericarp
Punicacortein AC27H22O18634.45Bark
Punicacortein BC27H22O18634.45Bark
PunicafolinC41H30O26938.66Leaves
PunigluconinC34H26O23802.56Bark
StrictininC27H22O18634.45Leaves
Tellimagrandin IC34H26O22786.56Leaves, pericarp
TercatainC34H26O22786.56Leaves
2-O-galloyl-4,6(S,S) gallagoyl-D-glucoseC41H26O26934.63Bark
5-O-galloyl-punicacortein DC54H34O341222.8Leaves
Punicacortein CC47H26O301070.7Bark
Punicacortein DC47H26O301070.7Bark, heartwood
PunicalinC34H22O22782.53Bark, pericarp
PunicalaginC48H28O301084.7Bark, pericarp, peel
Terminalin/gallayldilactonC28H20O16602.37Pericarp
Ellagic Acid Derivatives
Ellagic acidC14H6O8302.19Fruit, pericarp, bark
Ellagic acid, 3,3′-di-O-methylC16H10O8330.25Seed
Ellagic acid, 3,3′, 4′-tri-O-methylC17H12O8344.27Seed
Ellagic acid, 3′-O-methyl-3, 4-methyleneC16H8O8328.23Heartwood
Eschweilenol CC20H16O12448.33Heartwood
Diellagic acid rhamnosyl(1-4) glucosideC40H30O24894.65Heartwood
Catechin and Procyanidins
(-)-CatechinC15H14O6290.27Juice
Catechin-(4,8)-gallocatechinC30H26O13594.52Peel
GallocatechinC15H14O7306.27Peel
Gallocatechin-(4,8)-catechinC30H26O13594.52Peel
Gallocatechin-(4,8)-gallocatechinC30H26O14610.52Peel
Procyanidin B1C30H26O12578.52Juice
Procyanidin B2C30H26O12578.52Juice
Anthocyanins and Anthocyanidins
CyanidinC15H11O6287.24Peel
Cyanidin-3-glucosideC21H21O11449.38Juice
Cyanidin-3,5-diglucosideC27H31O16611.52Juice
(Continued)
Cyanidin-3-rutinosideC27H31O15595.53Juice
DelphinidinC15H11O7303.24Juice
Delphinidin-3-glucosideC21H21O12465.38Juice
Delphinidin 3, 5-diglucosideC27H31O17627.52Juice
Pelargonidin 3-glucosideC21H21O10433.38Juice
Pelargonidin 3,5-diglucosideC27H31O15595.53Juice
Flavonols
Apigenin-4′-O-β-D-glucosideC21H20O11448.32Leaves
KaempferolC15H10O6286.24Peel, fruit
LuteolinC15H10O6286.24Peel, fruit
Luteolin-3′-O-β-D-glucosideC21H20O10432.11Leaves
Luteolin-4′-O-β-D-glucosideC21H20O10432.11Leaves
Luteolin-3′-O-β-D-XylosideC21H18O10418.09Leaves
MyricetinC15H10O8318.04Fruit
QuercetinC15H10O7302.04Peel, fruit
QuercimeritrinC21H20O12464.38Fruit
Quercetin-3-O-rutinosideC27H30O16610.52Fruit
Quercetin-3,4′-dimethyl ether 7-O-α-L-arabinofuranosyl-(1-6)-β-D-glucosideC28H32O16624.54Bark, peel
Eriodictyol-7-O-α-Larabinofuranosyl (1-6)-β-D-glucosideC26H30O15582.51Leaves
Naringenin 4′-methylether 7-O-α-L-arabinofuranosyl (1-6)-β-D-glucosideC27H32O14580.53Leaves
Organic Acids
Caffeic acidC9H8O4180.16Juice
Chlorogenic acidC16H18O9345.31Juice
Cinnamic acidC9H8O2148.16Juice
Citric acidC6H8O7192.12Juice
o-Coumaric acidC9H8O3164.16Juice
p-Coumaric acidC9H8O3164.16Juice
Ferulic acidC10H10O4194.18Juice
Gallic acidC7H6O5170.12Juice
L-Malic acidC4H6O5134.09Juice
Oxalic acidC2H2O490.03Juice
Protocatechuic acidC7H6O4154.12Juice
Quinic acidC7H12O6192.17Juice
Succinic acidC4H6O4118.09Juice
Organic Acids
Caffeic acidC9H8O4180.16Juice
Chlorogenic acidC16H18O9345.31Juice
Cinnamic acidC9H8O2148.16Juice
Citric acidC6H8O7192.12Juice
o-Coumaric acidC9H8O3164.16Juice
p-Coumaric acidC9H8O3164.16Juice
Ferulic acidC10H10O4194.18Juice
Gallic acidC7H6O5170.12Juice
L-Malic acidC4H6O5134.09Juice
Oxalic acidC2H2O490.03Juice
Protocatechuic acidC7H6O4154.12Juice
(Continued)
Quinic acidC7H12O6192.17Juice
Succinic acidC4H6O4118.09Juice
Tartaric acidC4H6O6150.09Juice
Simple Gallyol Derivatives
BrevifolinC12H8O6248.19Leaves
Brevifolin carboxylic acidC13H8O8292.2Leaves
Brevifolin carboxylic acid-10-monosulphateC13H7KO10S394.25Leaves
1,2,3-Tri-O-galloyl-β-D-glucoseC27H24O18448.32Leaves
1,2,4-Tri-O-galloyl-β-D-glucoseC27H24O18286.24Leaves
1,2,6-Tri-O-galloyl-β-D-glucoseC27H24O18286.24Leaves
1,4,6-Tri-O-galloyl-β-D-glucoseC27H24O18432.11Leaves
1,3,4-Tri-O-galloyl-β-D-glucoseC27H24O18432.11Leaves
1,2, 4, 6-Tetra-O-galloyl-β-D-glucoseC34H28O22418.09Leaves
1,2,3,4, 6-Pent-O-galloyl-β-D-glucoseC41H32O26318.04Leaves
Methyl gallateC8H8O5302.04Heratwood
3,4,8,9,10-pentahydroxy-dibenzo[b,d]pyran-6-oneC13H8O7464.38Leaves
Fatty Acids and Triglycerides
Eicosenoic acidC20H40O2312.53Seed oil
Linoleic acidC18H32O2280.45Seed oil
Linolenic acidC18H30O2278.43Seed oil
Oleic acidC18H34O2282.46Seed oil
Palmitic acidC16H32O2256.42Seed oil
Punicic acidC18H30O2278.43Seed oil
Stearic acidC18H36O2284.48Seed oil
Tri-O-punicylglycerolC57H92O6873.34Seeds
Di-O-punicyl-O-octadeca-8Z-11Z-13E-trienylglycerolC57H92O6873.34Seeds
1-O-trans, cis, trans, octadecatrienol glycerolC21H36O4352.51Seed oil
1-O-isopentyl-3-O-octadec-2-enoyl glycerolC26H50O4426.67Seed oil
Sterols and Terpenoids
Asiatic acidC30H48O5488.7Juice
Betulinic acidC30H48O3456.70Seed
CholesterolC27H46O386.65Seed oil
DaucosterolC35H60O6576.85Seed
EstroneC18H22O2270.37Seed oil
EstradiolC18H24O2272.38Seed oil
EstriolC18H24O3288.38Seed oil
Friedooleanan-3-oneC30H50O426.72Bark
β-SitosterolC29H50O414.71Seed oil, leaves, stem
StigmasterolC29H48O412.69Seed oil
TestosteroneC19H28O2288.42Seed oil
Ursolic acidC30H48O3456.70Seed
Alkaloids
HygrineC8H15NO141.21Root bark
(Continued)
NorhygrineC7H13NO127.18Root bark
PelletierineC8H15NO141.21Bark
N-methyl pelletierineC9H17NO155.24Bark
SedridineC8H17NO143.23Bark
PseudopelletierineC9H15NO153.22Bark
Nor-pseudopelletierineC8H13NO139.19Bark
2,3,4,5-tetrahydro-6-propenyl-pyridineC8H13N123.20Bark
3,4,5,6-tetrahydro-a-methyl-2-pyridine ethanolC8H15NO141.21Bark
1-(2,5-dyihydroxy-phenyl)-pyridium chlorideC11H10ClNO2223.66Leaves
Other Compounds
Coniferyl 9-O-[β-D-apiofuranosyl-(1-6)]-O-β-D-glucopyranosideC21H30O12474.46Seed
PseudopelletierineC9H15NO153.22Bark
Nor-pseudopelletierineC8H13NO139.19Bark
2,3,4,5-tetrahydro-6-propenyl-pyridineC8H13N123.20Bark
3,4,5,6-tetrahydro-a-methyl-2-pyridine ethanolC8H15NO141.21Bark
1-(2,5-dyihydroxy-phenyl)-pyridium chlorideC11H10ClNO2223.66Leaves
Other Compounds
Coniferyl 9-O-[β-D-apiofuranosyl-(1-6)]-O-β-D-glucopyranosideC21H30O12474.46Seed
Sinapyl 9-O-[β-D-apiofuranosyl-(1-6)]-O-β-D-glucopyranosideC18H36O2284.48Seed
PhenylethylrutinosideC57H92O6873.34Seeds
Icariside D1C57H92O6873.34Seeds
MannitolC21H36O4352.51Bark

Pg has been shown to inhibit breast cancer cell lines MCF-7 and MB-MDA-231 by hindering angiogenesis, tumor growth, invasiveness, proliferation, and induction of apoptosis (53, 95-97). An inhibitory effect of Pg has been shown on lung and skin cancer models (44, 98). Moreover, Wongwattanasathien et al. have shown the inhibitory effect of Pg on HL-60 human leukemia cells through inhibition of proliferation and differentiation of these cell lines (91). Pg has been shown to have anti-atherosclerotic effects through protection of endothelial function, destructive effects on reactive oxygen species such as NO by its antioxidant properties (99), increase MPM uptake of oxidized LDL, and decrease of lipid peroxidation and cholesterol levels (100). Furthermore, Pg has been shown to have anti-hyperlipidemia activity through activation of peroxisome proliferators activated receptor (PPAR-α), which can decrease cardiac uptake and circulating lipids (101). Furthermore, Pg decreases cholesterol levels by decreasing absorption and increasing fecal excretion of cholesterol, as well as effecting cholesterol metabolism through HMG-CoA reductase and sterol O-acyltransfrase (102). It has also been demonstrated that Pg has anti-hypertensive effects, with inhibited serum angiotensin converting enzyme (ACE) and decreased systolic blood pressure being observed in hypertensive patients (103). Reduced myocardial ischemia and improved myocardial perfusion were also caused by Pg (104). In an animal model of diabetes, Pg resulted in lower serum C-peptides, a pro-insulin metabolite marker for endogenously secreted insulin, by 23 percent compared to baseline levels in diabetic patients (105). Pg has also shown effectiveness in controlling oral inflammation (106) as well as bacterial (107) and fungal counts in periodontal diseases (108), and Candida associated denture stomatitis (109). Pg has been found to have antibacterial properties against oral bacteria (106, 109), including methicilin-resistance Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA) (110). Kasai et al. have also shown the protective properties of Pg against UV-induced damage and skin pigmentation, compared to the placebo (111). Azadzoi et al. found anti-erectile dysfunction properties for Pg, measured by intracavernous blood flow and penile erection in a rabbit model of arteriogenic erectile dysfunction (112).Therefore, it could be used in male infertility to improve epidermal sperm concentration, sperm motility, decrease the number of abnormal sperms, and increase spermatogenic cell density (113). Pg hasneuroprotective properties in neonatal hypoxia-ischemic brain injury (18, 114) and preventive effects on Alzheimer’s disease, as shown in animal models (improved learning of water maze tasks) (115). Anti-obesity effects (116) have also been described for Pg. COX-2 has been involved in spatial memory retention and may impair the memory by injecting it intra-hippocampal, in rats (117). The inhibitory effect of Pg on COX-2 could be valuable in inhibiting memory impairment.

Conclusions

In this review, we gathered all the published studies on Pg without date elimination. However attempts were made to explain the new data. Iran is considered to be the primary origin of Pg. Pg juice, fruit, and extracts have been used extensively in the folk medicine of ancient cultures for various medicinal properties (118). Pg has been shown to possess phytochemicals which may hold pharmacological and toxicological properties (6). Nevertheless, the exact effects and involved mechanisms for the pharmacological and toxicological effects of many of these chemicals remain to be cleared. Nowadays, the use of herbal products or medicinal plants, because of their safety and efficiency in the prevention and/or treatment of several chronic diseases, are being extensively investigated worldwide.

The information presented in this review article which was obtained from in-vitro, in-vivo and clinical trial investigations has shown some of the pharmacological and toxicological mechanisms and properties of PE. These properties include anti-oxidative, anti-inflammatory, anticancer, anti-angiogenesis, and inhibitory effect on invasion/motility, cell cycle arrest, apoptosis, stimulation of cell differentiation and anti-mutagenic effects, and inhibitory effects on vital enzymes such as COX, LOX, CYP450, PLA2, ODC, CA, 17β-HSDs and SP. Existence of these pharmacological and toxicological mechanisms and properties and interference of several signaling pathways including PI3K/AKT, mTOR, PI3K, Bcl-X, Bax, Bad, MAPK, ERK1/2, P38, JNK, and caspase relation to Pg, suggest that Pg can be extensively used as a possible therapy for prevention and treatment of several types of diseases including prostate cancer, colon cancer, breast cancer, lung cancer, skin cancer, leukemia, anti-atherosclerosis, hyperlipidemia, hypertension, myocardial ischemia, myocardial perfusion, diabetes, oral inflammation, infection, anti-erectile dysfunction, male infertility, neonatal hypoxia-ischemic brain injury, alzheimer and obesity.

References

  • 1.

    Facciola S. Cornucopia: a Source Book of Edible Plants. Vista, California: Kampong Publications; 1990. 166 p.

  • 2.

    Sheidai M, Khandan M, Nasre ES. B-chromosomes in Iranian pomegranate (Punica granatum) cultivars. Pak. J. Bot. 2007;39:85-91.

  • 3.

    Stover E, Mercure EW. The pomegranate: a new look at the fruit of paradise. Hort. Sci. 2007;42:1088-1092.

  • 4.

    Kim YH, Choi EM. Stimulation of osteoblastic differentiation and inhibition of interleukin-6 and nitric oxide in MC3T3-E1 cells by pomegranate ethanol extract. Phytother. Res. 2009;23:737-739. [PubMed ID: 19107859].

  • 5.

    Ricci D, Giamperi L, Bucchini A, Fraternale D. Antioxidant activity of Punica granatum fruits. Fitoterapia. 2006;77:310-312. [PubMed ID: 16698192].

  • 6.

    Seeram NP, Schulman RN, Heber D. Pomegranates: Ancient Roots to Modern Medicine. Boca Raton: Taylor and Francis Group; 2006. p. 5-8.

  • 7.

    Karageuzyan KG. Oxidative stress in the molecular mechanism of pathogenesis at different diseased states of organism in clinics and experiment. Curr. Drug TargetsInflamm. Allergy. 2005;4:85-98.

  • 8.

    Ohshima H, Tazawa H, Sylla BS, Sawa T. Prevention of human cancer by modulation of chronic inflammatory process. Mutat. Res. 2005;591:110-122. [PubMed ID: 16083916].

  • 9.

    Garcea G, Dennison AR, Steward WP, Berry DP. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatol. 2005;5:514-529.

  • 10.

    Noda Y, Kaneyuki T, Mori A, Packer L. Antioxidant activities of pomegranate fruit extract and its anthocyanidins: delphinidin, cyanidin, and pelargonidin. J. Agric. Food Chem. 2002;50:166-171. [PubMed ID: 11754562].

  • 11.

    Miguel G, Dandlen S, Antunes D, Neves A, Martins D. The effect of two methods of pomegranate (Punica granatum L) juice extraction on quality during storage at 4˚C. J. Biomed. Biotech. 2004;5:332-337.

  • 12.

    Okamoto JM, Hamamoto YO, Yamato H, Yoshimura H. Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice. J. Ethnopharmacol. 2004;92:93-101. [PubMed ID: 15099854].

  • 13.

    Guo S, Deng Q, Xiao J, Xie B, Sun Z. Evaluation of antioxidant activity and preventing DNA damage effect of pomegranate extracts by chemiluminescence method. J. Agric. Food. Chem. 2007;55:3134-3140. [PubMed ID: 17381116].

  • 14.

    Kulkarni AP, Mahal HS, Kapoor S, Aradhya SM. In-vitro studies on the binding, antioxidant, and cytotoxic actions of punicalagin. J. Agric. Food Chem. 2007;55:1491-500. [PubMed ID: 17243704].

  • 15.

    Zahin M, Aqil F, Ahmad I. Broad spectrum antimutagenic activity of antioxidant active fraction of Punica granatum L. peel extracts.Mutat. Res. 2010;703:99-107.

  • 16.

    Faria A, Monteiro R, Azevedo I, Calhau C. Pomegranate juice effects on cytochrome P450S expression: in-vivo studies. J. Med. Food. 2007;10:643-639. [PubMed ID: 18158835].

  • 17.

    Ajaikumar KB, Asheef M, Babu BH, Padikkala J. The initiation of gastric mucosal injury by Punica granatum L. (pomegranate) methanolic extract. J. Ethnopharmcol. 2005;96:171-176.

  • 18.

    Loren DJ, Seeram NP, Schulman RN, Holtzman DM. Maternal dietary supplementation withpomegranate juice is neuroproective in an animal model of neonatal hypoxia-ischemic brain injury. Ped. Res. 2005;57:858-864.

  • 19.

    Faria A, Monteiro R, Mateus N, Azevedo I, Calhau C. Effect of pomegranate (Punica granatum) juice intake on hepatic oxidative stress. Eur. J. Nutr. 2007;46:271-8. [PubMed ID: 17514376].

  • 20.

    Aviram M, Dornfeld L, Kaplan M, Coleman R, Gaitini D, Nitecki S, Hofman A, Rosenblat M, Volkova N, Presser D, Attias J, Hayek T, Fuhrman B. Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular disease: studies in atherosclerotic mice and in humans. Drugs Exp. Clin. Res. 2002;28:49-62. [PubMed ID: 12224378].

  • 21.

    Pacheco-Palencia LA, Noratto G, Hingorani L, Talcott ST, Mertens-Talcott SU. Protective effects of standardized pomegranate (Punica granatum L.) polyphenolic extract in ultraviolet-irradiated human skin fibroblasts. J. Agric. Food Chem. 2008;56:8434-8441. [PubMed ID: 18717570].

  • 22.

    Rosenblat M, Volkova N, Aviram M. Pomegranate juice (PJ) consumption antioxidative properties on mouse macrophages, but not PJ beneficial effects on macrophage cholesterol and triglyceride metabolism, are mediated via PJ-induced stimulation of macrophage PON2. Atherosclerosis. 2010;212:86-92. [PubMed ID: 20537330].

  • 23.

    Fuhrman B, Volkova N, Aviram M. Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. J. Nutr. Biochem. 2005;16:570-576. [PubMed ID: 16115546].

  • 24.

    Mohan M, Waghulde H, Kasture S. Effect of pomegranate juice on angiotensin II-induced hypertension in diabetic Wistar rats. Phytother. Res. 2010;2:196-203.

  • 25.

    Aviram M, Rosenblat M, Gaitini D, Nitecki S, Hoffman A, Dornfeld L, Volkova N, Presser D, Attias J, Liker H, Hayek T. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin. Nutr. 2004;23:423-433. [PubMed ID: 15158307].

  • 26.

    Nigris F, Balestrieri ML, Williams-Ignarro S, D’Armiento FP, Fiorito C, Ignarro LJ, Napoli C. The influence of pomegranate fruit extract in comparison to regular pomegranate juice and seed oil on nitric oxide and arterial function in obese Zucker rats. Nitric Oxide. 2007;17:50-54. [PubMed ID: 17553710].

  • 27.

    Basu A, Penugonda K. Pomegranate juice: a heart-healthy fruit juice. Nutr. Rev. 2009;67:49-56. [PubMed ID: 19146506].

  • 28.

    Balkwill F, Charles KA, Mantovani A. Smoldering inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211-217. [PubMed ID: 15766659].

  • 29.

    Simmons DL, Buckley CD. Some new and not so new, anti-inflammatory targets. Curr. Opn. Pharmacol. 2005;5:394-397.

  • 30.

    Schubert SY, Lansky EP, Neeman I. Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. J. Ethnopharmacol. 1999;66:11-17. [PubMed ID: 10432202].

  • 31.

    Rahimi HR, Arasoo M, Shiri M. Punica granatum is more effective to prevent gastric disorders induced by Helicobacter pylori or any other stimulator in humans. Asian J. Plan. Sci. 2011;10:380-382.

  • 32.

    Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. Clin. Invest. 2006;116:4-15.

  • 33.

    Ahmed S, Wang N, Hafeez BB, Cheruvu VK, Haqqi TM. Punica granatum L. extract inhibits IL-1beta-induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-kappa B in human chondrocytes in-vitro. Nutr. 2005;135:2096-2102.

  • 34.

    Mix KS, Mengshol JA, Benbow U, Vincenti MP, Sporn MB, Brinckerhoff CE. A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum. 2001;44:1096-1104. [PubMed ID: 11352241].

  • 35.

    Larrosa M, González-Sarrías A, Yáñez-Gascón MJ, Selma MV, Azorín-Ortuño M, Toti S, Tomás-Barberán F, Dolara P, Espín JC. Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J. Nutr. Biochem. 2010;21:717-725. [PubMed ID: 19616930].

  • 36.

    Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes. Dev. 2004;18:2195-224. [PubMed ID: 15371334].

  • 37.

    Toklu HZ, Dumlu MU, Sehirli O, Ercan F, Gedik N, Gökmen V, Sener G. Pomegranate peel extract prevents liver fibrosis in biliary-obstructed rats. J. Pharm. Pharmacol. 2007;59:1287-95. [PubMed ID: 17939210].

  • 38.

    Shukla M, Gupta K, Rasheed Z, Khan KA, Haqqi TM. Consumption of hydrolyzable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis. Nutr. 2008;24:733-43.

  • 39.

    Koyama S, Cobb LJ, Mehta HH, Seeram NP, Heber D, Pantuck AJ, Cohen P. Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Horm. IGF Res. 2010;20:55-62. [PubMed ID: 19853487].

  • 40.

    Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H, Klatte T, Belldegrun A, Moro A, Henning SM, Mo D, Aronson WJ, Pantuck A. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol. Cancer Ther. 2008;7:2662-71. [PubMed ID: 18790748].

  • 41.

    Sturgeon SR, Ronnenberg AG. Pomegranate and breast cancer: possible mechanisms of prevention. Nutr. Rev. 2010;68:122-128. [PubMed ID: 20137057].

  • 42.

    Kasimsetty SG, Bialonska D, Reddy MK, Ma G, Khan SI, Ferreira D. Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins. J. Agric. Food Chem. 2010;58:2180-2187. [PubMed ID: 20112993].

  • 43.

    Khan SA. The role of pomegranate (Punica granatum L.) in colon cancer. Pak. J. Pharm. Sci. 2009;22:346-348. [PubMed ID: 19553187].

  • 44.

    Khan N, Afaq F, Kweon MH, Kim K, Mukhtar H. Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res. 2007;67:3475-3482. [PubMed ID: 17389758].

  • 45.

    Hong MY, Seeram NP, Heber D. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. J. Nutr. Biochem. 2008;19:848-855. [PubMed ID: 18479901].

  • 46.

    Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, Sartippour M, Harris DM, Rettig M, Suchard MA, Pantuck AJ, Belldegrun A, Heber D. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J. Agric. Food Chem. 2007;55:7732-7. [PubMed ID: 17722872].

  • 47.

    Malik A, Mukhtar H. Prostate cancer prevention through pomegranate fruit. Cell Cycle. 2006;5:371-373. [PubMed ID: 16479165].

  • 48.

    Eatock MM, Schatzlein A, Kaye SB. Tumor vasculature as a target for anticancer therapy. Cancer Treat. Rev. 2000;26:191-204. [PubMed ID: 10814561].

  • 49.

    Pfeffer U, Ferrari N, Morini M, Benelli R, Noonan DM, Albini A. Antiangiogenic activity of chemopreventive drugs. Int. J. Biol. Markers. 2003;18:70-74. [PubMed ID: 12699068].

  • 50.

    Scappaticci FA. The therapeutic potential of novel antiangiogenic therapies. Expert. Opin. Investig. Drugs. 2003;12:923-932.

  • 51.

    Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part II): Functional impact on tumor tissue. Histol. Histopathol. 2002;17:623-37. [PubMed ID: 11962762].

  • 52.

    Hartlapp I, Abe R, Saeed RW, Peng T, Voelter W, Bucala R, Metz CN. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in-vivo. FASEB. J. 2001;15:2215-2224. [PubMed ID: 11641248].

  • 53.

    Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, Carr RE, Oikawa TandLanskyEP. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in-vitro and in-vivo. Angiogenesis. 2003;6:121-128. [PubMed ID: 14739618].

  • 54.

    Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J. 2004;18:1123-1125. [PubMed ID: 15132991].

  • 55.

    Chung TW, Moon SK, Lee YC, Kim JG, Ko JH, Kim CH. Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells. Arch. Biochem. Biophys. 2002;408:147-154. [PubMed ID: 12464265].

  • 56.

    Aslam MN, Lansky EP, Varani J. Pomegranate as a cosmeceutical source: pomegranate fractions promote proliferation and procollagen synthesis and inhibit matrix metalloproteinase-1 production in human skin cells. J. Ethnopharmacol. 2006;103:311-318. [PubMed ID: 16221534].

  • 57.

    Hwang HJ, Park HJ, Chung HJ, Min HY, Park EJ, Hong JY, Lee SK. Inhibitory effects of caffeic acid phenethyl ester on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells. J. Nutr. Biochem. 2006;17:356-362. [PubMed ID: 16214327].

  • 58.

    Watanabe H, Nakanishi I, Yamashita K, Hayakawa T, Okada Y. Matrix metalloproteinase-9 (92 kDagelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion. J. Cell. Sci. 1993;104:991-999. [PubMed ID: 8314909].

  • 59.

    Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell. Biol. 1997;74:111-122. [PubMed ID: 9352216].

  • 60.

    Khan GN, Gorin MA, Rosenthal D, Pan Q, Bao LW, Wu ZF, Newman RA, Pawlus AD, Yang P, Lansky EP, Merajver SD. Pomegranate fruit extract impairs invasion and motility in human breast cancer. Integr. Cancer Ther. 2009;8:242-53. [PubMed ID: 19815594].

  • 61.

    Lansky EP, Harrison G, Froom P, Jiang WG. Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel. Invest. New. Drugs. 2005;23:121-122. [PubMed ID: 15744587].

  • 62.

    Dai Z, Nair V, Khan M, Ciolino HP. Pomegranate extract inhibits the proliferation and viability of MMTV-Wnt-1 mouse mammary cancer stem cells in-vitro. Oncol. Rep. 2010;24:1087-1091. [PubMed ID: 20811693].

  • 63.

    Khan N, Hadi N, Afaq F, Syed DN, Kweon MH, Mukhtar H. Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis. 2007;28:163-73. [PubMed ID: 16920736].

  • 64.

    Syed DN, Malik A, Hadi N, Sarfaraz S, Afaq F, Mukhtar H. Photochemopreventive effect of pomegranate fruit extract on UVA-mediated activation of cellular pathways in normal human epidermal keratinocytes. Photochem. Photobiol. 2006;82:398-405. [PubMed ID: 16613491].

  • 65.

    Albrecht M, Jiang W, Kumi-Diaka J, Lansky EP, Gommersall LM, Patel A, Mansel RE, Neeman I, Geldof AA, Campbell MJ. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J. Med. Food. 2004;7:274-283. [PubMed ID: 15383219].

  • 66.

    Li TM, Chen GW, Su CC, Lin JG, Yeh CC, Cheng KC, Chung JG. Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res. 2005;25:971-979. [PubMed ID: 15868936].

  • 67.

    Fahham N, Ghahremani MH, Sardari S, Vaziri B, Ostad SN. Simulation of different truncated p16(INK4a) forms and in silico study of interaction with Cdk4. Cancer Inform. 2009;7:1-11. [PubMed ID: 19352455].

  • 68.

    Fahham N, Sardari S, Ostad SN, Vaziri B, Ghahremani MH. C-terminal domain of p16(INK4a) is adequate in inducing cell cycle arrest, growth inhibition and CDK4/6 interaction similar to the full length protein in HT-1080 fibrosarcoma cells. J. Cell. Biochem. 2010;111:1598-606. [PubMed ID: 21053367].

  • 69.

    Grossmann ME, Mizuno NK, Schuster T, Cleary MP. Punicic acid is an omega-5 fatty acid capable of inhibiting breast cancer proliferation. Int. J. Oncol. 2010;36:421-426. [PubMed ID: 20043077].

  • 70.

    Koyama S, Cobb LJ, Mehta HH, Seeram NP, Heber D, Pantuck AJ, Cohen P. Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. GrowthHorm. IGF Res. 2010;20:55-62.

  • 71.

    Sabri A, Ziaee AA, Ostad SN, Alimoghadam K, Ghahremani MH. Crosstalk of EGF-directed MAPK signalling pathways and its potential role on EGF-induced cell proliferation and COX-2 expression in human mesenchymal stem cells. Cell. Biochem. Funct. 2011;29:64-70. [PubMed ID: 21264892].

  • 72.

    Abkhezr M, Keramati AR, Ostad SN, Davoodi J, Ghahremani MH. The time course of Akt and ERK activation on XIAP expression in HEK 293 cell line. Mol. Biol. Rep. 2010;37:2037-42. [PubMed ID: 19649722].

  • 73.

    Larrosa M, Tomás-Barberán FA, Espín JC. The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J. Nutr. Biochem. 2006;17:611-625. [PubMed ID: 16426830].

  • 74.

    Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA. 2005;102:14813-14818. [PubMed ID: 16192356].

  • 75.

    Lansky EP, Jiang W, Mo H, Bravo L, Froom P, Yu W, Harris NM, Neeman I, Campbell MJ. Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest. New. Drugs. 2005;23:11-20. [PubMed ID: 15528976].

  • 76.

    Kimura Y, Ito H, Hatano T. Effects of mace and nutmeg on human cytochrome P450 3A4 and 2C9 activity. Biol. Pharm. Bull. 2010;33:1977-1982. [PubMed ID: 21139236].

  • 77.

    Bachrach U. Polyamines and cancer: minireview article. Amino Acids. 2004;26:307-309. [PubMed ID: 15290334].

  • 78.

    Hora JJ, Maydew ER, Lansky EP, Dwivedi C. Chemopreventive effects of pomegranate seed oil on skin tumor development in CD1 mice. J. Med. Food. 2003;6:157-161. [PubMed ID: 14585180].

  • 79.

    Khalifah RG. Reflections on Edsall's carbonic anhydrase: paradoxes of an ultra fast enzyme. Biophys. Chem. 2003;100:159-170. [PubMed ID: 12646362].

  • 80.

    Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 2004;19:199-229. [PubMed ID: 15499993].

  • 81.

    Karaer O, Oruç S, Koyuncu FM. Aromatase inhibitors: possible future applications. Acta Obstet. Gynecol. Scand. 2004;83:699-706. [PubMed ID: 15255840].

  • 82.

    Adams LS, Zhang Y, Seeram NP, Heber D, Chen S. Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in-vitro. Cancer Prev. Res. 2010;3:108-113.

  • 83.

    Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes. Dev. 2000;14:2123-2133. [PubMed ID: 10970876].

  • 84.

    Moraes TJ, Chow CW, Downey GP. Proteases and lung injury. Crit. Care. Med. 2003;31:189-194.

  • 85.

    Kwak HM, Jeon SY, Sohng BH, Kim JG, Lee JM, Lee KB, Jeong HH, Hur JM, Kang YH, Song KS. beta-Secretase (BACE1) inhibitors from pomegranate (Punica granatum) husk. Arch. Pharm. Res. 2005;28:1328-1332. [PubMed ID: 16392663].

  • 86.

    Iwasaki R, Ito K, Ishida T, Hamanoue M, Adachi S, Watanabe T, Sato Y. Catechin, green tea component, causes caspase-independent necrosis-like cell death in chronic myelogenous leukemia. Cancer Sci. 2009;100:349-356. [PubMed ID: 19200260].

  • 87.

    Saito M, Saito K, Kunisaki N, Kimura S. Green tea polyphenols inhibit metalloproteinase activities in the skin, muscle, and blood of rainbow trout. J. Agric. Food Chem. 2002;50:7169-7174. [PubMed ID: 12428978].

  • 88.

    Benelli R, Venè R, Bisacchi D, Garbisa S, Albini A. Anti-invasive effects of green tea polyphenol epigallocatechin-3-gallate (EGCG), a natural inhibitor of metallo and serine proteases. Biol. Chem. 2002;383:101-105. [PubMed ID: 11928805].

  • 89.

    dePascual-Teresa S, Santos-Buelga C, Rivas-Gonzalo JC. Quantitative analysis of flavan-3-ols in Spanish foodstuffs and beverages. J. Agric. Food Chem. 2000;48:5331-5337. [PubMed ID: 11087482].

  • 90.

    Kawaii S, Lansky EP. Differentiation-promoting activity of pomegranate (Punica granatum) fruit extracts in HL-60 human promyelocytic leukemia cells. J. Med. Food. 2004;7:13-8. [PubMed ID: 15117547].

  • 91.

    Wongwattanasathien O, Kangsadalampai K, Tongyonk L. Antimutagenicity of some flowers grown in Thailand. Food Chem. Toxicol. 2010;48:1045-1051. [PubMed ID: 20100534].

  • 92.

    Adams LS, Seeram NP, Aggarwal BB, Takada Y, Sand D, Heber D. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J. Agric. Food Chem. 2006;54:980-985. [PubMed ID: 16448212].

  • 93.

    Khedmat S, Seyedabadi M, Ghahremani MH, Ostad SN. Cyclooxygenase 2 plays a role in Emdogain-induced proliferation. J. Periodontal. Res. 2011;46:67-73. [PubMed ID: 20860590].

  • 94.

    Habibollahi P, Jamshidiha M, Daryani NE, Jahanzad I, Ghahremani MH, Ostad SN. Correlation between inducible nitric oxide synthase and cyclooxygenase-2 expression in human colorectal adenocarcinoma: a cross-sectional study. Pathol. Oncol. Res. 2010;16:327-335. [PubMed ID: 20069397].

  • 95.

    Mehta R, Lanksy EP. Breast cancer chemopreventive properties of pomegranate (Punica granatum) fruit extracts in a mouse mammary organ culture. Eur. J. Cancer. Prev. 2004;13:345-348. [PubMed ID: 15554563].

  • 96.

    Kim ND, Mehta R, Yu W, Neeman I, Livney T, Amichay A, Poirier D, Nicholls P, Kirby A, Jiang W, Mansel R, Ramachandran C, Rabi T, Kaplan B, Lansky E. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast. Cancer. Res. Treat. 2002;71:203-217. [PubMed ID: 12002340].

  • 97.

    Jeune MA, Kumi-Diaka J, Brown J. Anticancer activities of pomegranate extracts and genistein in human breast cancer cells. J. Med. Food. 2005;8:469-475. [PubMed ID: 16379557].

  • 98.

    Afaq F, Saleem M, Krueger CG, Reed JD, Mukhtar H. Anthocyanin and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK , NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice. Int. J. Cancer. 2005;113:423-433. [PubMed ID: 15455341].

  • 99.

    Ignarro LJ, Byrns RE, Sumi D, de NigrisF, Napoli C. Pomegranate juice protects nitric oxide against oxidative destruction and enhances the biological actions of nitric oxide. Nitric Oxide. 2006;15:93-102. [PubMed ID: 16626982].

  • 100.

    Aviram M, Volkova N, Coleman R, Dreher M, Reddy MK, Ferreira D, Rosenblat M. Pomegranate phenolics from the peels, arils, and flowers are antiatherogenic: studies in-vivo in atherosclerotic apolipoprotein E-deficient (E°) mice and in-vitro cultured macrophages and lipoproteins. J. Agric. Food Chem. 2008;56:1148-1157. [PubMed ID: 18173244].

  • 101.

    Huang TH, Peng G, Kota BP, Li GQ, Yamahara J, Roufogalis BD, Li Y. Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids. Br. J. Pharmacol. 2005;145:767-774. [PubMed ID: 15880139].

  • 102.

    Esmaillzadeh A, Tahbaz F, Gaieni I, Alavi-Majd H, Azadbakht L. Cholesterol-lowering effect of concentrated pomegranate juice consumption in type II diabetic patients with hyperlipidemia. Int. J. Vitam. Nutr. Res. 2006;76:147-151. [PubMed ID: 17048194].

  • 103.

    Aviram M, Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis. 2001;158:195-198. [PubMed ID: 11500191].

  • 104.

    Sumner MD, Elliott-Eller M, Weidner G, Daubenmier JJ, Chew MH, Marlin R, Raisin CJ, Ornish D. Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. Am. J. Cardiol. 2005;96:810-814. [PubMed ID: 16169367].

  • 105.

    Rosenblat M, Hayek T, Aviram M. Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages. Atherosclerosis. 2006;187:363-371. [PubMed ID: 16226266].

  • 106.

    Sastravaha G, Gassmann G, Sangtherapitikul P, Grimm WD. Adjunctive periodontal treatment with Centellaasiatica and Punica granatum extracts in supportive periodontal therapy. J. Int. Acad. Periodontol. 2005;7:70-79. [PubMed ID: 16022023].

  • 107.

    Menezes SM, Cordeiro LN, Viana GS. Punica granatum (pomegranate) extract is active against dental plaque. J. HerbPharmacother. 2006;6:79-92.

  • 108.

    Sastravaha G, Yotnuengnit P, Booncong P, Sangtherapitikul P. Adjunctive periodontal treatment with Centellaasiatica and Punica granatum extracts. A preliminary study. J. Int. Acad. Periodontol. 2003;5:106-115.

  • 109.

    Vasconcelos LC, Sampaio MC, Sampaio FC, Higino JS. Use of Punica granatum as an antifungal agent against candidosis associated with denture stomatitis. Mycoses. 2003;46:192-196. [PubMed ID: 12801361].

  • 110.

    Machado TdeBM, Leal ICR, Amaral ACF, dos SantosKRN, da SilvaMG, Kuster RM. Antimicrobial ellagitannin of Punica granatum fruits. J. Braz. Chem. Soc. 2002;13:606-610.

  • 111.

    Kasai K, Yoshimura M, Koga T, Arii M, Kawasaki S. Effects of oral administration of ellagic acid-rich pomegranate extract on ultraviolet-induced pigmentation in the human skin. J. Nutr. Sci. Vitaminol. 2006;52:383-388. [PubMed ID: 17190110].

  • 112.

    Azadzoi KM, Schulman RN, Aviram M, Siroky MB. Oxidative stress in arteriogenic erectile dysfunction: prophylactic role of antioxidants. J. Urol. 2005;174:386-393. [PubMed ID: 15947695].

  • 113.

    Türk G, Sönmez M, Aydin M, Yüce A, Gür S, Yüksel M, Aksu EH, Aksoy H. Effects of pomegranate juice consumption on sperm quality, spermatogenic cell density, antioxidant activity, and testosterone level in male rats. Clin. Nutr. 2008;27:289-296. [PubMed ID: 18222572].

  • 114.

    West T, Atzeva M, Holtzman DM. Pomegranate polyphenols and resveratrol protect the neonatal brain against hypoxic-ischemic injury. Dev. Neurosci. 2007;29:363-372. [PubMed ID: 17762204].

  • 115.

    Hartman RE, Shah A, Fagan AM, Schwetye KE, Parsadanian M, Schulman RN, Finn MB, Holtzman DM. Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer’s disease. Neurobiol. Dis. 2006;24:506-515. [PubMed ID: 17010630].

  • 116.

    Lei F, Zhang XN, Wang W, Xing DM, Xie WD, Su H, Du LJ. Evidence of antiobesity effects of the pomegranate leaf extract in high-fat diet induced obese mice. Int. J. Obes. 2007;31:1023-1029.

  • 117.

    Sharifzadeh M, Naghdi N, Khosrovani S, Ostad SN, Sharifzadeh K, Roghani A. Post-training intrahippocampal infusion of the COX-2 inhibitor celecoxib impaired spatial memory retention in rats. Eur. J. Pharmacol. 2005;511:159-66. [PubMed ID: 15792784].

  • 118.

    Longtin R. The pomegranate: nature›s power fruit? J. Natl. Cancer Inst. 2003;95:346-348. [PubMed ID: 12618495].